In gouty patients, urate lowering therapies (ULTs) are recommended to bring serum uric acid
(SUA) levels below 6.0 mg/dL, with the aim of dissolving urate depositions, thereby reducing …

Hyperuricemia is caused by reduced renal/extrarenal excretion and overproduction of uric
acid. It is affected by genetic predisposition related to uric acid transporters and by visceral …

Hyperuricemia (elevated serum uric acid) is prevalent, and an important mediator of gout, an
increasingly common condition. In addition, hyperuricemia is associated with metabolic …

Recent epidemiological data suggest a progressive increase of serum levels of uric acid
worldwide. This rise in the prevalence of hyperuricemia may be related to the epidemic …

Objectives: In this article, the results of clinical and experimental studies that examine the
association of hyperuricemia and gout with hypertension and kidney disease are presented …

Purine metabolism in the circulatory system yields uric acid as its final oxidation product,
which is believed to be linked to the development of gout and kidney stones. Hyperuricemia …

Uric acid is the final oxidation product of purine metabolism in circulation and has been
associated with the occurrence of gout and kidney stones. Type 2 diabetes mellitus and …

Hyperuricemia is associated with hypertension, kidney disease, vascular and cardiovascular
(CV) events. In experimental models, the inhibition of hepatic uricase induces …

Hyperuricemia, ie increased serum uric acid (UA) concentration, is a common problem in
clinical practice. While there are clear guidelines concerning management of symptomatic …

Substantial evidence suggests that chronic hyperuricemia is an independent risk factor for
hypertension, metabolic syndrome, chronic kidney disease (CKD) and cardiovascular …